| Title |
Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report
|
|---|---|
| Published in |
OncoTargets and therapy, December 2016
|
| DOI | 10.2147/ott.s115892 |
| Pubmed ID | |
| Authors |
Cristina Bagacean, Adrian Tempescul, Mariana Patiu, Bogdan Fetica, Horia Bumbea, Mihnea Zdrenghea |
| Abstract |
Large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative disorder of transformed natural killer or T-cells attributed to chronic exposure to the proinflammatory cytokine IL-15. Diagnosis of the majority of T-cell LGLL is established by documenting clonal large granular lymphocytes (LGLs) in peripheral blood, by morphology and immunophenotype. The proteasome inhibitor bortezomib is known to target molecular pathways downstream of the IL-15 receptor signaling and has been proposed as a therapy in these patients. We report an uncommon presentation of LGLL with chronic neutropenia lacking typical blood LGLs, which failed to respond to bortezomib but obtained a very good partial remission with a classical methotrexate regimen. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 8 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 2 | 25% |
| Other | 1 | 13% |
| Lecturer | 1 | 13% |
| Professor | 1 | 13% |
| Student > Ph. D. Student | 1 | 13% |
| Other | 1 | 13% |
| Unknown | 1 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 38% |
| Nursing and Health Professions | 1 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 13% |
| Immunology and Microbiology | 1 | 13% |
| Agricultural and Biological Sciences | 1 | 13% |
| Other | 0 | 0% |
| Unknown | 1 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 December 2016.
All research outputs
#16,720,137
of 25,371,288 outputs
Outputs from OncoTargets and therapy
#982
of 3,016 outputs
Outputs of similar age
#249,842
of 416,429 outputs
Outputs of similar age from OncoTargets and therapy
#25
of 57 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 416,429 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.